Group 6D: HR+ Breast Cancer; Treatment Resistance

Poster #PO1-23-10: Multi-omics analysis identifies the mechanism in cross-resistance to endocrine therapy and CDK4/6 inhibitor in breast cancer.

Poster #PS03-04: Tumor immune microenvironment modulates resistance to estrogen suppression in ER+ breast cancer.